Submit to Vaccines Review for Vaccines Propose a Special Issue

Journal Browser

Fluctuating Paradigms in Neuroinflammation: Experimental Research Insights for New Clinical Approaches to Multiple Sclerosis

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Pathogens-host Immune Interface".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 9723

Share This Special Issue

Special Issue Editor

Dr. Giovanni Ferrara

E-Mail Website
Guest Editor

Experimental Neuroscience Lab, IRCCS San Martino Hospital, 16132 Genoa, Italy
Interests: neuroimmunology; neuroinflammation; multiple sclerosis; experimental autoimmune encephalomyelitis; encephalitogenic response T and dendritic cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Multiple sclerosis (MS), an autoimmune and inflammatory disease of the central nervous system, is characterized by the primary destruction of myelin. The most common CNS immune-mediated disease where immunopathology is thought to be mediated by myelin-reactive CD4+ T helper cells is the paradigm of neuroinflammation. The T cell response in MS is regulated at multiple levels, and it depends on the interaction with other immune cells in the periphery as well as with CNS-resident microglia, astrocytes and oligodendrocytes. However, other concomitant unknown neuroinflammatory processes may play a role in the pathogenesis of MS, finally causing myelin disruption, neuronal death, a loss of motor functions and cognitive impairment.

In this Special Issue, manuscripts reporting how the new experimental data promote the understanding of pathological processes in neuroinflammation, and how those data generate new clinical approaches to MS, are welcome. We aim at providing a collection of high-impact manuscripts dissecting the unknown or lesser studied neuroinflammatory pathological processes that could lead to a new therapeutical approach to MS. The final goal of this Special Issue is to help neuroscientists to reconsider their basic knowledge of MS.

Dr. Giovanni Ferrara
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

multiple sclerosis
neuroinflammation
new pathogenetic mechanism
new therapeutic approach
T encephalitogenic response
dendritic cell activation

Published Papers (3 papers)

Download All Papers

Research

Jump to: Other

11 pages, 1154 KiB

Open AccessArticle

Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells

by Giovanni Ferrara, Federico Ivaldi, Gianluigi Mancardi, Nicole Kerlero de Rosbo and Antonio Uccelli

Vaccines 2021, 9(7), 736; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9070736 - 03 Jul 2021

Cited by 1 | Viewed by 2173

Abstract

Multiple sclerosis (MS) is a neurological disorder characterized by an autoimmune response, demyelinating plaques and axonal damage. Intense immunosuppression (II) followed by autologous hematopoietic stem cell transplantation has been proposed as a treatment in severe forms of MS. We have used murine relapsing-remitting (RR) experimental autoimmune encephalomyelitis (RR-EAE) to evaluate the transplantation of syngeneic bone marrow cells (BMC) after II, in combination with mesenchymal stem cells (MSCs) as a new therapeutic adjunct capable of improving immune reconstitution. In EAE-affected mice treated with BMC alone, we observed a drastic reduction in the clinical course only during the early RR phase of the disease. There was no difference in the RR-EAE clinical course between mice treated with BMC alone and co-transplanted mice. To analyze the immune reconstitution, we quantified the circulating immune cells in naïve and RR-EAE-affected mice after II, with BMC alone or in combination with MSC. Although II resulted in reduced numbers of circulating immune cells, reconstitution did not differ in co-transplanted mice. During the early phase of the disease, IL-4 was significantly elevated in co-transplanted mice, as compared to those treated with BMC alone. These data suggest that BMC transplantation after II transiently ameliorates the clinical symptoms of RR-EAE, but that co-transplantation with MSC has no synergistic effect. Full article

(This article belongs to the Special Issue Fluctuating Paradigms in Neuroinflammation: Experimental Research Insights for New Clinical Approaches to Multiple Sclerosis)

► Show Figures

Figure 1

13 pages, 1501 KiB

Open AccessCommunication

Specific Treatment Exists for SARS-CoV-2 ARDS

by Badar Kanwar, Chul Joong Lee and Jong-Hoon Lee

Vaccines 2021, 9(6), 635; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9060635 - 10 Jun 2021

Cited by 9 | Viewed by 4131

Abstract

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsone’s effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimer’s disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p < 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Bötzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2. Full article

(This article belongs to the Special Issue Fluctuating Paradigms in Neuroinflammation: Experimental Research Insights for New Clinical Approaches to Multiple Sclerosis)

► Show Figures

Figure 1

Other

Jump to: Research

14 pages, 592 KiB

Open AccessProtocol

Neurocognitive Profile of the Post-COVID Condition in Adults in Catalonia—A Mixed Method Prospective Cohort and Nested Case–Control Study: Study Protocol

by Rosalia Dacosta-Aguayo, Noemí Lamonja-Vicente, Carla Chacón, Lucia Amalía Carrasco-Ribelles, Pilar Montero-Alia, Anna Costa-Garrido, Rosa García-Sierra, Victor M. López-Lifante, Eduard Moreno-Gabriel, Marta Massanella, Josep Puig, Jose A. Muñoz-Moreno, Lourdes Mateu, Anna Prats, Carmina Rodríguez, Maria Mataró, Julia G. Prado, Eva Martínez-Cáceres, Concepción Violán and Pere Torán-Monserrat

Vaccines 2022, 10(6), 849; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines10060849 - 26 May 2022

Cited by 2 | Viewed by 2220

Abstract

The diagnosis of the post-COVID condition is usually achieved by excluding other diseases; however, cognitive changes are often found in the post-COVID disorder. Therefore, monitoring and treating the recovery from the post-COVID condition is necessary to establish biomarkers to guide the diagnosis of symptoms, including cognitive impairment. Our study employs a prospected cohort and nested case–control design with mixed methods, including statistical analyses, interviews, and focus groups. Our main aim is to identify biomarkers (functional and structural neural changes, inflammatory and immune status, vascular and vestibular signs and symptoms) easily applied in primary care to detect cognitive changes in post-COVID cases. The results will open up a new line of research to inform diagnostic and therapeutic decisions with special considerations for cognitive impairment in the post-COVID condition. Full article

(This article belongs to the Special Issue Fluctuating Paradigms in Neuroinflammation: Experimental Research Insights for New Clinical Approaches to Multiple Sclerosis)

► Show Figures